Handing KB, Shabalin IG, Kassaar O, Khazaipoul S, Blindauer CA, Stewart AJ, et al
The "best" GLP-1 medication is the one that works for your body, fits your medical history, and is accessible to you
US biotech Regeneron (Nasdaq: REGN) has reported positive Phase III results from a Chinese trial of its obesity candidate olatorepatide, a dual GLP-1/GIP receptor agonist licensed from Hansoh Pharmaceutical, showing substantial weight loss alongside comparatively mild gastrointestinal side effects
Some studies have found that reducing brain pressure through procedures like spinal taps provides sudden relief from migraines, indicating intracranial pressure might play a central role
Discussion The emergence of depressive symptoms with semaglutide use in this case is puzzling and necessitates further inquiry
The synthetic GLP-1 in obesity drugs lingers in the body for weeks after being injected